BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer. 2002;99:491-504. [PMID: 11992538 DOI: 10.1002/ijc.10376] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 2007;6:3219-28. [PMID: 18065493 DOI: 10.1158/1535-7163.MCT-07-0275] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
2 Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017;409:66-80. [PMID: 28888998 DOI: 10.1016/j.canlet.2017.08.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
3 Liang X, Du J, Liu Y, Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, Chen YH, Sun W. The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 2007;12:1827-36. [DOI: 10.1007/s10495-007-0114-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
4 Rigillo N, Meloni T, Torelli M, Schettini F. [Haptoglobin and orosomucoid in the blood in a case of congenital afibrinogenemia and in the family of the patient]. Boll Soc Ital Biol Sper. 1968;44:81-83. [PMID: 5651986 DOI: 10.1186/1471-2407-5-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 1.1] [Reference Citation Analysis]
5 Steinert DM, Blakely LJ, Salganick J, Trent JC. Molecular targets in therapy for human soft-tissue and bone sarcomas. Curr Oncol Rep 2003;5:295-303. [DOI: 10.1007/s11912-003-0069-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
6 Brunetti G, Oranger A, Carbone C, Mori G, Sardone FR, Mori C, Celi M, Faienza MF, Tarantino U, Zallone A, Grano M, Colucci S. Osteoblasts display different responsiveness to TRAIL-induced apoptosis during their differentiation process. Cell Biochem Biophys 2013;67:1127-36. [PMID: 23677859 DOI: 10.1007/s12013-013-9616-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
7 Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthop Res 2003;21:949-57. [DOI: 10.1016/s0736-0266(03)00062-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Toki S, Kobayashi E, Yoshida A, Ogura K, Wakai S, Yoshimoto S, Yonemori K, Kawai A. A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma. Bone Joint J 2019;101-B:745-52. [PMID: 31154837 DOI: 10.1302/0301-620X.101B6.BJJ-2018-1207.R1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM, Tsai W, Cole GW Jr, Schrump DS, Nguyen DM. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 2006;8:446-57. [PMID: 16820090 DOI: 10.1593/neo.05823] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
10 Araki S, Nakayama Y, Hori A, Yoshimura K. Biomarkers for predicting the sensitivity of cancer cells to TRAIL-R1 agonistic monoclonal antibody. Cancer Lett 2010;292:269-79. [PMID: 20056315 DOI: 10.1016/j.canlet.2009.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003;13:539-53. [PMID: 14655759 DOI: 10.1111/j.1750-3639.2003.tb00484.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
12 Grisendi G, Spano C, D'souza N, Rasini V, Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns JS, Fiorcari S, Granchi D, Baldini N, Horwitz EM, Guarneri V, Conte P, Paolucci P, Dominici M. Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas: Adipose MSC with TRAIL Target Sarcomas. Stem Cells 2015;33:859-69. [DOI: 10.1002/stem.1903] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
13 Faienza MF, D'Amato G, Chiarito M, Colaianni G, Colucci S, Grano M, Corbo F, Brunetti G. Mechanisms Involved in Childhood Obesity-Related Bone Fragility. Front Endocrinol (Lausanne) 2019;10:269. [PMID: 31130918 DOI: 10.3389/fendo.2019.00269] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
14 Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res 2016;34:1716-24. [PMID: 26867804 DOI: 10.1002/jor.23192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004;42:410-5. [PMID: 15049011 DOI: 10.1002/pbc.20019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
16 Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41. [PMID: 15846298 DOI: 10.1038/sj.bjc.6602487] [Cited by in Crossref: 229] [Cited by in F6Publishing: 190] [Article Influence: 13.5] [Reference Citation Analysis]
17 Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS, Nguyen DM. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 2007;12:55-71. [PMID: 17136498 DOI: 10.1007/s10495-006-0484-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
18 Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 2003;17:464-6. [PMID: 12631584 DOI: 10.1096/fj.02-0534fje] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 3.6] [Reference Citation Analysis]
19 Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D’Arcy P, Zhivotovsky B, Childs R, Lundqvist A. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer. 2013;133:1643-1652. [PMID: 23504627 DOI: 10.1002/ijc.28163] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
20 Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009;11:R13. [PMID: 19171073 DOI: 10.1186/ar2603] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
21 Findlay DM, Welldon K, Atkins GJ, Howie DW, Zannettino AC, Bobyn D. The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials 2004;25:2215-27. [PMID: 14741587 DOI: 10.1016/j.biomaterials.2003.09.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 122] [Article Influence: 7.7] [Reference Citation Analysis]
22 Rifas L, Arackal S, Weitzmann MN. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem 2003;88:650-9. [DOI: 10.1002/jcb.10436] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
23 Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013;169:1723-44. [PMID: 23638798 DOI: 10.1111/bph.12238] [Cited by in Crossref: 121] [Cited by in F6Publishing: 115] [Article Influence: 15.1] [Reference Citation Analysis]
24 Daigeler A, Klein-Hitpass L, Chromik MA, Müller O, Hauser J, Homann HH, Steinau HU, Lehnhardt M. Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer 2008;8:313. [PMID: 18959781 DOI: 10.1186/1471-2407-8-313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
25 Pal S, Shankar BS, Sainis KB. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells. Cytokine 2013;64:196-207. [PMID: 23972545 DOI: 10.1016/j.cyto.2013.07.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
26 Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-gossmann D, Dimanche-boitrel M. Cytotoxicity of TRAIL/Anticancer Drug Combinations in Human Normal Cells. Annals of the New York Academy of Sciences 2006;1090:209-16. [DOI: 10.1196/annals.1378.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
27 Shin JN, Seo YW, Kim M, Park SY, Lee MJ, Lee BR, Oh JW, Seol DW, Kim TH. Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J Biol Chem 2005;280:10509-15. [PMID: 15634686 DOI: 10.1074/jbc.M413865200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
28 Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Vα24+ NKT cell-mediated cytotoxicity. Int J Cancer 2006;119:1630-7. [DOI: 10.1002/ijc.22019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
29 Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer. 2004;109:661-667. [PMID: 14999771 DOI: 10.1002/ijc.20008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
30 Wu X, Ogawa O, Kakehi Y. TRAIL and Chemotherapeutic Drugs in Cancer Therapy. TRAIL (TNF-Related Apoptosis-Inducing Ligand). Elsevier; 2004. pp. 365-83. [DOI: 10.1016/s0083-6729(04)67019-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
31 Papenfuss K, Cordier SM, Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008;12:2566-2585. [PMID: 19210756 DOI: 10.1111/j.1582-4934.2008.00514.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
32 Shamimi-noori S, Yeow W, Ziauddin MF, Xin H, Tran TLN, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, Nguyen DM. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 2008;15:356-70. [DOI: 10.1038/sj.cgt.7701120] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
33 Nguyen DM, Yeow W, Ziauddin MF, Baras A, Tsai W, Reddy RM, Chua A, Cole GW, Schrump DS. The Essential Role of the Mitochondria-Dependent Death-Signaling Cascade in Chemotherapy-Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells: Amplified Caspase 8 Is Indispensable for Combination-Mediated Massive Cell Death. The Cancer Journal 2006;12:257-73. [DOI: 10.1097/00130404-200607000-00004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
34 Yang BF, Xiao C, Li H, Yang SJ. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation. Clin Exp Pharmacol Physiol 2007;34:1245-51. [PMID: 17973862 DOI: 10.1111/j.1440-1681.2007.04711.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
35 Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 2003;89:206-14. [PMID: 12838325 DOI: 10.1038/sj.bjc.6601021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
36 Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8. [DOI: 10.1016/s1535-6108(02)00132-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
37 Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai LM, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006;119:944-54. [DOI: 10.1002/ijc.21939] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
38 Zhou J, Huang Z, Wang Z, Liu S, Grandien A, Ernberg I, He Z, Zhang X. Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma. Oncotarget 2017;8:43853-65. [PMID: 28029652 DOI: 10.18632/oncotarget.14126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Houghton JA. Antimetabolites. In: Gewirtz DA, Holt SE, Grant S, editors. Apoptosis, Senescence, and Cancer. Totowa: Humana Press; 2007. pp. 361-82. [DOI: 10.1007/978-1-59745-221-2_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Zannettino AC, Findlay DM, Evdokiou A. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 2009;8:2969-80. [PMID: 19808976 DOI: 10.1158/1535-7163.MCT-09-0745] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
41 Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J, Ding X, Gao S. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine 2011;6:1991-2005. [PMID: 21976975 DOI: 10.2147/IJN.S24094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
42 Yoon AR, Hong J, Yun CO. Adenovirus-mediated decorin expression induces cancer cell death through activation of p53 and mitochondrial apoptosis. Oncotarget 2017;8:76666-85. [PMID: 29100340 DOI: 10.18632/oncotarget.20800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
43 Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281-91. [PMID: 15160330 DOI: 10.1002/cncr.20270] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 4.4] [Reference Citation Analysis]
44 Stamatopoulos A, Stamatopoulos T, Gamie Z, Kenanidis E, Ribeiro RDC, Rankin KS, Gerrand C, Dalgarno K, Tsiridis E. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. J Bone Oncol 2019;16:100231. [PMID: 30956944 DOI: 10.1016/j.jbo.2019.100231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
45 Garg G, Gibbs J, Belt B, Powell MA, Mutch DG, Goedegebuure P, Collins L, Piwnica-Worms D, Hawkins WG, Spitzer D. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer 2014;14:35. [PMID: 24447304 DOI: 10.1186/1471-2407-14-35] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
46 Pena ES, Graham-Gurysh EG, Bachelder EM, Ainslie KM. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. Int J Mol Sci 2021;22:13160. [PMID: 34884965 DOI: 10.3390/ijms222313160] [Reference Citation Analysis]
47 Tummala S, Kumar MNS, Pindiprolu SK. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Delivery 2016;23:3505-19. [DOI: 10.1080/10717544.2016.1199606] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
48 Li Z, Zhang J, Tang J, Wang R. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors. Oncotarget 2016;7:84388-97. [PMID: 27768597 DOI: 10.18632/oncotarget.12756] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
49 Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A, Blair HC. Expression and function of TNF-family proteins and receptors in human osteoblasts☆. Bone 2003;33:760-70. [DOI: 10.1016/j.bone.2003.07.006] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.5] [Reference Citation Analysis]
50 Sun J, Fu Z, Fang C, Li J. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents: . Chinese Medical Journal 2007;120:400-4. [DOI: 10.1097/00029330-200703010-00010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
52 Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, Ito N, Ogawa O. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer. 2003;104:409-417. [PMID: 12584736 DOI: 10.1002/ijc.10948] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
53 Nakamura A, Ly C, Cipetić M, Sims NA, Vieusseux J, Kartsogiannis V, Bouralexis S, Saleh H, Zhou H, Price JT, Martin TJ, Ng KW, Gillespie MT, Quinn JM. Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone 2007;40:305-15. [DOI: 10.1016/j.bone.2006.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
54 Humphreys RC, Halpern W. Trail Receptors: Targets for Cancer Therapy. Programmed Cell Death in Cancer Progression and Therapy. Dordrecht: Springer Netherlands; 2008. pp. 127-58. [DOI: 10.1007/978-1-4020-6554-5_7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
55 Cao H, Yang Y, Lü L, Liu S, Wang P, Tao X, Wang L, Xiang T. Attenuated Salmonella Typhimurium Carrying TRAIL and VP3 Genes Inhibits the Growth of Gastric Cancer Cells in Vitro and in Vivo. Tumori 2010;96:296-303. [DOI: 10.1177/030089161009600218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
56 Moon MH, Jeong JK, Seo JS, Seol JW, Lee YJ, Xue M, Jackson CJ, Park SY. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med 2011;43:138-45. [PMID: 21297379 DOI: 10.3858/emm.2011.43.3.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
57 Li XA, Fang DC, Yang LQ, Zhang RG, Si PR. Cytotoxicity of TRAIL on colon cancer cell line SW480. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 298-301 [DOI: 10.11569/wcjd.v11.i3.298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Neeson PJ, Hsu AK, Chen YR, Halse HM, Loh J, Cordy R, Fielding K, Davis J, Noske J, Davenport AJ, Lindqvist-Gigg CA, Humphreys R, Tai T, Prince HM, Trapani JA, Smyth MJ, Ritchie DS. Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. Oncoimmunology 2015;4:e1038011. [PMID: 26405606 DOI: 10.1080/2162402X.2015.1038011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
59 Liang X, Qu Z, Zhang Z, Du J, Liu Y, Cui M, Liu H, Gao L, Han L, Liu S, Cao L, Zhao P, Sun W. Blockade of preS2 down-regulates the apoptosis of HepG2.2.15 cells induced by TRAIL. Biochemical and Biophysical Research Communications 2008;369:456-63. [DOI: 10.1016/j.bbrc.2008.02.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
60 Guiho R, Biteau K, Heymann D, Redini F. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. Future Oncol 2015;11:535-42. [PMID: 25675131 DOI: 10.2217/fon.14.293] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
61 Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 2010;16:2591-604. [PMID: 20406839 DOI: 10.1158/1078-0432.CCR-09-2443] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
62 Vondalova Blanarova O, Jelinkova I, Szoor A, Skender B, Soucek K, Horvath V, Vaculova A, Andera L, Sova P, Szollosi J, Hofmanova J, Vereb G, Kozubik A. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis 2010;32:42-51. [DOI: 10.1093/carcin/bgq220] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
63 Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin 2005;26:1373-81. [PMID: 16225761 DOI: 10.1111/j.1745-7254.2005.00206.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
64 Yarapureddy S, Abril J, Foote J, Kumar S, Asad O, Sharath V, Faraj J, Daniel D, Dickman P, White-Collins A, Hingorani P, Sertil AR. ATF6α Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma. Neoplasia 2019;21:516-32. [PMID: 31029032 DOI: 10.1016/j.neo.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
65 Coutinho L, Oliveira H, Pacheco AR, Almeida L, Pimentel F, Santos C, Ferreira de Oliveira JMP. Hesperetin-etoposide combinations induce cytotoxicity in U2OS cells: Implications on therapeutic developments for osteosarcoma. DNA Repair 2017;50:36-42. [DOI: 10.1016/j.dnarep.2016.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
66 Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-8. [PMID: 19117685 DOI: 10.1016/j.ctrv.2008.11.006] [Cited by in Crossref: 196] [Cited by in F6Publishing: 180] [Article Influence: 14.0] [Reference Citation Analysis]
67 Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, Zannettino AC, Haynes DR, Findlay DM. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002;31:448-56. [PMID: 12398939 DOI: 10.1016/s8756-3282(02)00858-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
68 Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1. Experimental Cell Research 2004;298:560-73. [DOI: 10.1016/j.yexcr.2004.04.038] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
69 Jablonowski LJ, Conover D, Teraphongphom NT, Wheatley MA. Manipulating multifaceted microbubble shell composition to target both TRAIL-sensitive and resistant cells. J Biomed Mater Res A 2018;106:1903-15. [PMID: 29521001 DOI: 10.1002/jbm.a.36389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Nguyen DM, Hussain M. The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. J Bioenerg Biomembr 2007;39:13-21. [DOI: 10.1007/s10863-006-9055-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
71 Fang M, Mei X, Yao H, Zhang T, Zhang T, Lu N, Liu Y, Xu W, Wan C. β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo. Oncol Lett 2018;15:3957-64. [PMID: 29467906 DOI: 10.3892/ol.2018.7788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
72 Tomasetti M, Neuzil J. Vitamin E Analogues and Immune Response in Cancer Treatment. Vitamin E. Elsevier; 2007. pp. 463-91. [DOI: 10.1016/s0083-6729(07)76018-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
73 Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003;22:5427-35. [DOI: 10.1038/sj.onc.1206842] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
74 Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 2005;10:35-51. [PMID: 15711921 DOI: 10.1007/s10495-005-6060-0] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 5.2] [Reference Citation Analysis]
75 Gulati K, Prideaux M, Kogawa M, Lima-marques L, Atkins GJ, Findlay DM, Losic D. Anodized 3D-printed titanium implants with dual micro- and nano-scale topography promote interaction with human osteoblasts and osteocyte-like cells: 3D Printed Titanium Implants with Dual Micro- and Nano-Scale Topography. J Tissue Eng Regen Med 2017;11:3313-25. [DOI: 10.1002/term.2239] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
76 Cordier SM, Papenfuss K, Walczak H. From Biochemical Principles of Apoptosis Induction by TRAIL to Application in Tumour Therapy. In: Kalthoff H, editor. Death Receptors and Cognate Ligands in Cancer. Berlin: Springer Berlin Heidelberg; 2009. pp. 115-43. [DOI: 10.1007/400_2008_27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
77 Staege MS, Banning-eichenseer U, Weißflog G, Volkmer I, Burdach S, Richter G, Mauz-körholz C, Föll J, Körholz D. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Experimental Hematology 2008;36:886-96. [DOI: 10.1016/j.exphem.2008.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
78 Wu XX, Ogawa O, Kakehi Y. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines. Int J Urol 2004;11:164-70. [PMID: 15009365 DOI: 10.1111/j.1442-2042.2003.00766.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Choi SH, Tamura K, Khajuria RK, Bhere D, Nesterenko I, Lawler J, Shah K. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol Ther 2015;23:235-43. [PMID: 25358253 DOI: 10.1038/mt.2014.214] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
80 Yang X, Li Z, Wu Q, Chen S, Yi C, Gong C. TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors. Drug Deliv 2017;24:1526-36. [PMID: 28994313 DOI: 10.1080/10717544.2017.1384863] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
81 Zeise E, Weichenthal M, Schwarz T, Kulms D. Resistance of Human Melanoma Cells Against the Death Ligand TRAIL Is Reversed by Ultraviolet-B Radiation via Downregulation of FLIP. Journal of Investigative Dermatology 2004;123:746-54. [DOI: 10.1111/j.0022-202x.2004.23420.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
82 Ishii M, Iwai M, Harada Y, Kishida T, Asada H, Shin-ya M, Itoh Y, Imanishi J, Okanoue T, Mazda O. Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Letters 2007;245:134-43. [DOI: 10.1016/j.canlet.2005.12.040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
83 Van Valen F, Fulda S, Schäfer KL, Truckenbrod B, Hotfilder M, Poremba C, Debatin KM, Winkelmann W. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer 2003;107:929-40. [PMID: 14601052 DOI: 10.1002/ijc.11503] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
84 Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol. 2012;30:4141-4147. [PMID: 23071222 DOI: 10.1200/jco.2012.44.1055] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
85 Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-108. [PMID: 20819019 DOI: 10.1517/14728222.2010.519701] [Cited by in Crossref: 115] [Cited by in F6Publishing: 106] [Article Influence: 10.5] [Reference Citation Analysis]
86 Koschny R, Walczak H, Ganten TM. The promise of TRAIL—potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-35. [DOI: 10.1007/s00109-007-0194-1] [Cited by in Crossref: 145] [Cited by in F6Publishing: 135] [Article Influence: 9.7] [Reference Citation Analysis]
87 Todaro M, Orlando V, Cicero G, Caccamo N, Meraviglia S, Stassi G, Dieli F. Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity. PLoS One 2013;8:e65145. [PMID: 23762301 DOI: 10.1371/journal.pone.0065145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
88 Micheau O. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets 2003;7:559-73. [PMID: 12885274 DOI: 10.1517/14728222.7.4.559] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
89 Sharrow AC, Li Y, Micsenyi A, Griswold RD, Wells A, Monga SS, Blair HC. Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL. Exp Cell Res 2008;314:297-308. [PMID: 18022159 DOI: 10.1016/j.yexcr.2007.10.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
90 Mohr A, Chu T, Brooke GN, Zwacka RM. MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells. Cancers (Basel) 2019;11:E568. [PMID: 31010082 DOI: 10.3390/cancers11040568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
91 Wachtel M, Schäfer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010;36:318-27. [PMID: 20223596 DOI: 10.1016/j.ctrv.2010.02.007] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
92 Nicolaou KA, Liapis V, Evdokiou A, Constantinou C, Magiatis P, Skaltsounis AL, Koumas L, Costeas PA, Constantinou AI. Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells. Biochem Biophys Res Commun 2012;425:76-82. [PMID: 22820195 DOI: 10.1016/j.bbrc.2012.07.053] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
93 Karakurt S, AbuŞoĞlu G, Arituluk ZC. Comparison of anticarcinogenic properties of Viburnum opulus and its active compound p-coumaric acid on human colorectal carcinoma. Turk J Biol 2020;44:252-63. [PMID: 33110363 DOI: 10.3906/biy-2002-30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
94 Hassanvand Jamadi R, Yaghoubi H, Sadeghizadeh M. Brevinin-2R and Derivatives as Potential Anticancer Peptides: Synthesis, Purification, Characterization and Biological Activities. Int J Pept Res Ther 2019;25:151-60. [DOI: 10.1007/s10989-017-9656-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]